Immunotherapy Approvals for Nasopharyngeal Carcinoma
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has...
Progress Against Cancer
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has...
The FDA has approved nivolumab with ipilimumab as a first-line treatment for advanced liver cancer. The U.S. Food and...
The FDA has approved nivolumab with ipilimumab in certain patients with advanced colorectal cancer. The U.S. Food and Drug...
The FDA has approved the Immunotherapy durvalumab in combination with chemotherapy for certain patients with resectable bladder cancer. The...
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The...
The FDA has approved the multi-kinase inhibitor cabozantinib for certain adult and pediatric patients with rare neuroendocrine tumors. The...
The FDA has approved a PD-1 blockade treatment regimen for certain patients with advanced stomach and gastroesophageal cancer. The...
The FDA has approved a new combination regimen for certain patients with esophageal cell squamous cell carcinoma. The U.S....
The FDA has approved a CSF1 small molecule inhibitor for certain patients with symptomatic tenosynovial giant cell tumor. The...
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large...